How two proteins (STAT5 and OLIG2) may cause glioblastoma to resist treatment and return
STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22
This project looks at whether targeting the proteins STAT5 and OLIG2 can stop glioblastoma tumors from resisting therapy and coming back in people with GBM.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project ID | NIH-11284010 on NIH RePORTER |
What this research studies
From the patient's perspective, researchers will study tumor tissue and tumor-derived glioma stem cells, especially tumors that keep the EGFRvIII change, to see how STAT5 and OLIG2 drive treatment resistance. They will use lab-grown cell models and animal models to change STAT5 or OLIG2 activity and test how tumors respond to standard therapies. Molecular tests will map the signaling pathways (including non‑JAK routes) that let tumors survive treatment. The team aims to identify points where drugs or genetic approaches might make existing treatments work better and reduce recurrence.
Who could benefit from this research
Good fit: People with glioblastoma, particularly those whose tumors have EGFR amplification or the EGFRvIII mutation or who have tumors that are resistant to treatment, would be the most relevant candidates.
Not a fit: Patients without glioblastoma, or whose tumors do not show EGFR/STAT5 pathway activation, are unlikely to receive direct benefit from this work.
Why it matters
Potential benefit: If successful, this research could point to new drug targets or treatment combinations that make glioblastoma therapies more effective and reduce the chance the tumor comes back.
How similar studies have performed: Past efforts to target EGFR in glioblastoma have not improved survival, while targeting STAT5 has shown promising results in lab and animal studies for some cancers but remains largely untested in GBM patients.
Where this research is happening
Scottsdale, United States
- Mayo Clinic Arizona — Scottsdale, United States (Active)
Researchers
- Principal investigator: Tran, Nhan L — Mayo Clinic Arizona
- Study coordinator: Tran, Nhan L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.